Results from a recent publication call for the use of consistent nomenclature when describing the field of view captured by retinal images. The International Widefield Imaging Study Group has proposed the need for consistent nomenclature for widefield and ultra-widefield imaging based on normal anatomic landmarks. When describing the area captured by an imaging modality, it is important to be consistent in meaning so the capabilities of the technology are clear to the reader.
The panel defines ultra-widefield as images showing retinal anatomy anterior to the vortex vein ampullae in all four quadrants. Widefield is defined as an image centered on the fovea and includes the retina in all four quadrants posterior to and including the vortex vein ampullae. The panel recommends this standardized nomenclature for use in future publications1.
Over the last decade, many large studies have underlined the importance of appropriately imaging the periphery to support the detection and management of disease in a variety of areas including telemedicine screening2,3,4, diabetic retinopathy5,6, age-related maculardegeneration7, vascular disease8, pediatric retinal disease9, inflammatory disease10,11,12 and even some systemic diseases. Consistently, optomap imaging has been demonstrated to capture the widest field of view in a single capture of any imaging technology14,15,16,17.
As the leaders in ultra-widefield (UWF™) retinal imaging technology, Optos would like to invite you to join us at the International Vision Expo West (VEW) September 18-21 at the Sands Expo in Las Vegas. Explore what’s new at Optos by pre-scheduling your demonstration or stop by booth #MS6051 during the event.
This year Optos is a sponsor of the “Battle at the Sands: Imaging Track” competition where industry leaders, such as Dr. Mo Rafieetary, will present complex patient studies where imaging played a key role in diagnosis and treatment (and compete for bragging rights). After the winner is crowned, please join us at the workshop Wednesday, September 18th from 5-7pm in room 505 at the Sands Convention Center. Seats are limited.
Optos will also be participating in the OCT workshop, and demonstrating the functionality of our Monaco device — the only clinically-validated, 200-degree UWF retinal imaging device with integrated OCT. Monaco produces a 200-degree, single-capture optomap image in less than ½ second and also provides cross-sectional, 40-degree OCT views of retinal structures. Join us Thursday the 19th from 12:30-2:30pm and Friday the 20th from 12:15-2:15 in room 505 to explore the benefits of Optos UWF and OCT.
Age-related macular degeneration (AMD) is a leading cause of blindness in the United States, affecting most commonly, people over the age of 60 with increasing chances as you age, if you are overweight or if you have a family history of AMD.
As we approach our golden years, we are at a higher risk for particular eye diseases including age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, as well as eye conditions such as dry eye and low vision. More than 40 million Americans are currently 65 years or older, this number is expected to grow to more than 88 million by 2050 and not coincidentally, the number of Americans with age-related eye diseases is expected to double. Early detection and treatment are key to saving sight.
For some, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes. The loss of central vision in AMD can interfere with simple everyday activities, such as the ability to see faces, drive, read, write, or do close work, such as cooking or fixing things around the house.